CBRE vs TERN · P/E 43, rev $35.77B vs $6.12B cap
CBRE Group Inc Class A (CBRE) versus Terns Pharmaceuticals Inc (TERN) — a side-by-side from cached financials, not a winner call.
CBRE Group Inc Class A (CBRE) is a real estate services company listed on US.
Terns Pharmaceuticals Inc (TERN) is a biotechnology company listed on NASDAQ.
Latest reported CBRE revenue for 2024-12-31 was $35.77B. Net income was $1.04B. Revenue was up 12.0% from 2023-12-31 to 2024-12-31. CBRE currently screens at market cap $41.66B and trailing P/E 42.7.
Latest reported TERN revenue for 2022-12-31 was $0. Net income was -$60.3M. TERN currently screens at market cap $6.12B.
CBRE currently screens at market cap $41.66B and trailing P/E 42.7. TERN currently screens at market cap $6.12B.
Not investment advice. Open the CBRE and TERN stock pages for the full models.
Not investment advice.